Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389558 | 0.85 | GPR119 (0.46) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12914862 | 0.82 | SCN9A (0.35) | GPR119HRH1CCR3RECQL | |
| SCHEMBL388687 | 0.79 | GPR119 (0.49) | GPR119KCNH2 | |
| SCHEMBL390806 | 0.78 | GPR119 (0.37) | GPR119KCNH2 | |
| SCHEMBL1071774 | 0.75 | GPR119 (0.48) | GPR119CYP2C9KCNH2 | |
| SCHEMBL390808 | 0.74 | GPR119 (0.56) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391549 | 0.73 | GPR119 (0.47) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12835902 | 0.70 | GPR119 (0.42) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12914861 | 0.69 | SCN9A (0.36) | GPR119 | |
| SCHEMBL390529 | 0.68 | GPR119 (0.44) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292620-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2287165-A2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |